Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05607810 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 22, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Enrolling by Invitation to Active, Not Recruiting
    • Primary and study completion dates: Mar 2026 to Apr 2026
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective, observational study designed to evaluate the long-term safety and tolerability of ADVM-022 in participants with diabetic macular edema (DME). Participants who previously participated in the INFINITY parent study and received a single unilateral intravitreal dose of ADVM-022 are eligible for enrollment upon completion of the end of study visit in the parent study.
Trial Details
NCT Number NCT05607810
Lead Sponsor Adverum Biotechnologies, Inc.
Conditions
(from sponsor)		 Diabetic Macular Edema, Diabetic Retinopathy
Related terms Blindness, Diabetic Retinopathy, Eye Diseases, Retinal Diseases
Enrollment 22 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov